Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 65Sarcoma 40Neoplasm Metastasis 22Neoplasms 20Ovarian Neoplasms 17Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Recurrence 7Leiomyosarcoma 7Kidney Neoplasms 7Melanoma 6Liposarcoma 6Hemangiosarcoma 6Glioblastoma 6Fallopian Tube Neoplasms 6Thyroid Neoplasms 5Prostatic Neoplasms 5Neurofibrosarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Solid Tumors 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Dermatofibrosarcoma 4Clear-cell metastatic renal cell carcinoma 4Chondrosarcoma, Extraskeletal Myxoid 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

enzalutamide 2sipuleucel-T 1pazopanib 1capivasertib 1Watchful Waiting 1STA 9090 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Dutasteride 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of the Prostate × pazopanib × Clear all
NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

University of Utah

Phase 2 Completed
30 enrolled 10 charts
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡